What is Follistatin and how is it related to myostatin?

Follistatin is a protein that inhibits myostatin. Therapies discussed in the video aim to increase Follistatin levels, thereby reducing myostatin's activity and promoting muscle growth.

Are the $25,000 gene therapies for Follistatin FDA approved?

The video discusses a $25,000 gene therapy claiming to activate Follistatin. However, the discussion points to gray market peptides and the lack of FDA approval for such treatments.

How effective are gray market Follistatin peptides?

The use of gray market Follistatin peptides has been around for years, primarily in the bodybuilding community, with largely unimpressive results for most users. They require frequent injections due to short half-life and lack supporting data.

How much muscle mass can be gained by inhibiting myostatin later in life?

While complete myostatin knockout at birth doubles muscle mass in animals, inhibiting the gene in mature mice yielded a 25% increase. This suggests that the effects in developed humans might be significant but not 'game-changing'.

What are the results of early clinical trials for Follistatin therapies?

Phase one trials showed a statistically significant, but modest, increase in lean body mass (around 2 lbs) and a slight decrease in body fat. Other markers like inflammation remained unchanged, while metabolic markers showed concerning trends.

What are the potential side effects of Follistatin therapy?

Early data suggests potential negative trends in metabolic markers, including elevated resting glucose and insulin, and decreased HDLc and increased LDLc and triglycerides. The inhibition of FSH is also a noted, though less specific, effect of Follistatin.

How should I critically evaluate claims about muscle-building treatments?

Be wary of celebrity endorsements and anecdotal evidence, as they often lack context regarding diet, exercise, and other potential interventions. Focus on rigorously studied interventions with clear data and scientific literacy to discern valid information.

Key Moments

The amazing potential to increase muscle mass via myostatin inhibition | Peter Attia and Derek MPMD

Peter Attia MD

Science & Technology4 min read21 min video

Feb 29, 2024|109,293 views|1,576|193

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2 follistatin myostatin

Save to Pod

Key Moments

TL;DR

Myostatin inhibition's potential for muscle growth is discussed, with gene therapy vs. peptide efficacy debated.

Key Insights

Myostatin inhibition, through methods like FSTN gene therapy or peptide injections, theoretically promotes muscle growth by blocking myostatin's effects.

Myostatin knockout models in animals demonstrate a 'double muscle' phenotype, highlighting the gene's critical role in muscle development.

Early 'grey market' FSTN peptide products showed little to no observable effect in humans, suggesting issues with efficacy or administration.

Gene therapy approaches, such as introducing vectors to increase FSTN, are being explored but face questions about efficacy, cost, and measurement validation.

Claims of dramatic physique changes from FSTN therapy online may be exaggerated due to manipulative photography techniques, lighting, and temporary physiological states.

Clinical trials for FSTN in sarcopenia are underway, with early results showing modest lean body mass gains but also concerning metabolic and lipid marker changes.

The primary known mechanism of FSTN involves inhibiting FSH production, though a less specific isoform is used in current vectors, raising questions about off-target effects.

Scientific literacy is crucial to discern genuine results from marketing hype, especially concerning unproven therapies and celebrity endorsements.

THEORETICAL BASIS OF MYOSTATIN INHIBITION

The discussion centers on myostatin, a protein that naturally limits muscle growth. Inhibiting myostatin, therefore, holds theoretical potential for increasing muscle mass. This concept is vividly illustrated by remarkable 'myostatin knockout' animal models, including cattle and mice, which exhibit a 'double muscle' phenotype, essentially possessing double the muscle fibers of their normal counterparts. This dramatic effect underscores the gene's significant role in regulating muscle development and fuels interest in therapeutic interventions.

EARLY ATTEMPTS: FSTN PEPTIDE PRODUCTS

Historically, the bodybuilding community encountered over-the-counter research chemicals, specifically lyophilized FSTN peptide products. These were often marketed with claims of significant muscle gain, requiring frequent daily injections due to a short half-life. However, anecdotal evidence and observation suggested these products yielded minimal to no discernible results for the vast majority of users, leading to widespread skepticism about their efficacy. They were largely dismissed as ineffective and based on unsubstantiated claims without robust scientific backing.

GENE THERAPY AND VECTOR-BASED APPROACHES

More recent developments involve gene therapy, aiming to increase the body's production of FSTN protein, which in turn inhibits myostatin. This is achieved by introducing a viral or bacterial vector into the body. High costs, potentially $25,000 per treatment, are associated with these emerging therapies. A significant challenge lies in accurately measuring FSTN levels, as validated assays may not be readily available, raising questions about whether the administered therapy is effectively increasing the target protein and if this increase translates to meaningful biological effects.

CHALLENGES IN ASSESSING THERAPEUTIC EFFICACY

Evaluating the true impact of FSTN therapies is complicated by several factors. Anecdotal reports of dramatic transformations, often promoted by influencers, must be viewed critically. Visual evidence, such as before-and-after photos, can be easily manipulated through strategic posing, lighting, tanning, body oil, and even physiological states like post-exercise 'pump' or post-meal distension. These aesthetic tricks can create a significantly exaggerated appearance of change, making it difficult to distinguish genuine muscle growth from temporary or artificially enhanced visuals.

CLINICAL TRIAL DATA AND METABOLIC CONCERNS

Early clinical trials, including a phase one study with modest lean body mass gains of around two pounds, are yielding mixed results. While some metrics like lean body mass showed statistical significance, they were not overwhelmingly impressive. Critically, phase two trials targeting sarcopenia, while potentially showing more promising results over six months, have also revealed concerning trends in metabolic and lipid markers. These include elevated glucose and insulin, reduced HDL cholesterol, and increased triglycerides, suggesting potential adverse systemic effects that warrant careful investigation.

RESEARCH ON MATURE MICE AND MECHANISM UNCERTAINTIES

Further research, including an experiment where mature mice had near-complete myostatin gene blockage, showed a significant muscle mass increase of approximately 25%. However, this level of inhibition far exceeds what is likely achievable with current FSTN therapies and is still less dramatic than the effects seen in myostatin knockout models from birth. The discussion also touched upon FSTN's historical designation related to follicle-stimulating hormone (FSH) inhibition, raising questions about potential off-target effects of the isoforms used in current therapies, which might contribute to observed metabolic aberrations.

INTERPRETING RESULTS AND FUTURE RESEARCH NEEDS

Establishing the true efficacy and safety of myostatin inhibition therapies requires rigorous, unbiased research. Well-designed studies, ideally including placebo groups and controlling for variables like training stimulus, are crucial. The scientific community needs to carefully scrutinize claims, especially when financial incentives or conflicts of interest are present. A greater emphasis on scientific literacy among the public is essential to help individuals navigate the hype surrounding unproven performance-enhancing interventions.

Mentioned in This Episode

●Software & Apps

●Companies

●Studies Cited

●Concepts

●People Referenced

Myostatin Inhibition: Dos and Don'ts

Practical takeaways from this episode

Do This

Understand that myostatin knockout animals show extreme muscle growth.

Consider that Follistatin inhibits myostatin, theoretically promoting muscle gain.

Look for rigorously studied interventions, ideally with placebo controls.

Be aware that phase two trials are investigating Follistatin for sarcopenia.

Prioritize content from sources with high trust and low financial bias.

Develop scientific literacy to critically evaluate claims.

If considering treatment, understand the potential metabolic and hormonal side effects.

Avoid This

Do not rely on anecdotal evidence or celebrity endorsements for treatment efficacy.

Be skeptical of 'gray market' peptides like Follistatin without robust data or FDA approval.

Do not assume gene therapy or peptide injections will automatically lead to significant muscle gain.

Do not ignore potential photo manipulation tactics used in fitness transformation photos.

Do not dismiss potential negative metabolic markers (elevated glucose, insulin; reduced HDLc).

Do not rely on unvalidated assays for measuring drug levels.

Do not expect a 'game-changing' effect from inhibiting myostatin later in life, based on current data.

Phase One Trial Results for Follistatin Therapy

Data extracted from this episode

Metric	Result	Statistical Significance
Lean Body Mass Gain	Approx. 2 lbs	Statistically Significant
Body Fat Reduction	Approx. 1%	Statistically Significant (memory dependent)
Inflammation Markers	Stayed the same	N/A
Resting Glucose	Elevated	Likely Directional Trend
Insulin	Increased	Likely Directional Trend
HDLc	Decreased	Likely Directional Trend
Triglycerides	Increased	Likely Directional Trend
LDLc	Increased	Likely Directional Trend

Myostatin Gene Knockout Effects in Mice

Data extracted from this episode

Intervention	Muscle Mass Increase	Timing
Complete knockout at birth	>100% increase (doubled)	At birth
Near complete block (>99% mRNA deletion)	~25% increase	In mature mice (approx. 2 years old)

Common Questions

Myostatin is a protein that limits muscle growth. Inhibiting it is theoretically interesting because studies on myostatin knockout animals show a 'double-muscle' phenotype, indicating significantly increased muscle mass.

Topics

Myostatin Follistatin Photo Manipulation FSH Inhibition

Mentioned in this video

Studies & Research

Myostatin knockout mice

Animals, specifically mice, that have had their myostatin gene suppressed or removed, resulting in a double-muscled phenotype. These were a key visual during medical school that sparked interest in myostatin inhibition.

Myostatin knockout cattle

Cattle exhibiting a 'double-muscled' phenotype due to the absence of myostatin, looking extraordinarily muscular and out of proportion.

Drugs & Medications

SARMs

Selective Androgen Receptor Modulators mentioned as an alternative approach to building muscle that did not pan out as hoped by pharmaceutical companies, hinting at potential interest in Follistatin therapies.

Concepts

Follistatin

A protein that inhibits myostatin. Gene therapy and peptides aim to increase Follistatin levels to promote muscle growth. Its measurement and efficacy in humans are discussed.

Found this useful? Build your knowledge library

Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.

Try Summify free